Nevertheless, we observed activation of IFNγ and type-I IFN signaling, as well as other immune-response pathways (for example, antigen presentation), in both cancer and myeloid cells of DCP-IL-12/FLT3L-treated tumors compared to vehicle-treated tumors, as shown by unsupervised ranking of the most deregulated biological processes according to Reactome and Hallmark (Fig. 2i,j and Extended Data Fig. 5f,g). This evidence concerns the gene FLT3LG and cancer.